Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Non-cash Items: 2019-2025

Historic Non-cash Items for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $177.7 million.

  • Revolution Medicines' Non-cash Items rose 47.10% to $177.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $177.7 million, marking a year-over-year increase of 47.10%. This contributed to the annual value of $118.8 million for FY2024, which is 3.30% up from last year.
  • As of Q3 2025, Revolution Medicines' Non-cash Items stood at $177.7 million, which was down 0.45% from $178.5 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Non-cash Items ranged from a high of $179.6 million in Q1 2025 and a low of $44.4 million during Q3 2021.
  • Moreover, its 3-year median value for Non-cash Items was $118.8 million (2024), whereas its average is $125.5 million.
  • Over the last 5 years, Revolution Medicines' Non-cash Items had its largest YoY gain of 108.56% in 2021, and its largest YoY loss of 49.15% in 2021.
  • Quarterly analysis of 5 years shows Revolution Medicines' Non-cash Items stood at $84.0 million in 2021, then increased by 1.46% to $85.2 million in 2022, then surged by 35.02% to $115.0 million in 2023, then grew by 3.30% to $118.8 million in 2024, then skyrocketed by 47.10% to $177.7 million in 2025.
  • Its last three reported values are $177.7 million in Q3 2025, $178.5 million for Q2 2025, and $179.6 million during Q1 2025.